Department of Pathology, The Ohio State University Wexner Medical Center, Columbus, USA.
Department of Hematology, The Ohio State University Wexner Medical Center, Columbus, USA.
Haematologica. 2021 Jun 1;106(6):1608-1615. doi: 10.3324/haematol.2018.212571.
Mutations of the IGH variable region in patients with chronic lymphocytic leukemia (CLL) are associated with a favorable prognosis. Cytogenetic complexity (>3 unrelated aberrations) and translocations have been associated with an unfavorable prognosis. While mutational status of IGHV is stable, cytogenetic aberrations frequently evolve. However, the relationships of these features as prognosticators at diagnosis are unknown. We examined the CpG-stimulated metaphase cytogenetic features detected within one year of diagnosis of CLL and correlated these features with outcome and other clinical features including IGHV. Of 329 untreated patients, 53 (16.1%) had a complex karyotype (16.1%), and 85 (25.8%) had a translocation. Median time to first treatment (TFT) was 47 months. In univariable analyses, significant risk factors for shorter TFT (p3.5, log-transformed WBC, unmutated IGHV, complex karyotype, translocation, and FISH for trisomy 8, del(11q) and del(17p). In multivariable analysis, there was significant effect modification of IGHV status on the relationship between translocation and TFT (p=0.002). In IGHV mutated patients, those with a translocation had over 3.5 times higher risk of starting treatment than those without a translocation (p.
慢性淋巴细胞白血病 (CLL) 患者 IGH 可变区突变与预后良好相关。细胞遗传学复杂性(>3 种不相关的异常)和易位与预后不良相关。虽然 IGHV 的突变状态是稳定的,但细胞遗传学异常经常发生演变。然而,这些特征作为诊断时的预后因素的关系尚不清楚。我们研究了在 CLL 诊断后一年内检测到的 CpG 刺激的中期细胞遗传学特征,并将这些特征与结果以及其他临床特征(包括 IGHV)相关联。在 329 例未经治疗的患者中,53 例(16.1%)具有复杂核型(16.1%),85 例(25.8%)具有易位。首次治疗的中位时间(TFT)为 47 个月。在单变量分析中,TFT 较短的显著危险因素(p<0.001)包括:年龄≥65 岁、IGHV 未突变、复杂核型、易位、FISH 检测到三体 8、del(11q) 和 del(17p)。在多变量分析中,IGHV 状态对易位与 TFT 之间的关系存在显著的效应修饰作用(p=0.002)。在 IGHV 突变的患者中,有易位的患者开始治疗的风险是没有易位的患者的 3.5 倍以上(p<0.001)。